



Universiteit
Leiden
The Netherlands

Immune checkpoint inhibitors in mesothelioma

Disselhorst, M.J.

Citation

Disselhorst, M. J. (2022, October 25). *Immune checkpoint inhibitors in mesothelioma*. Retrieved from <https://hdl.handle.net/1887/3483978>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3483978>

Note: To cite this publication please use the final published version (if applicable).

List of publications

This thesis

Disselhorst MJ, Burgers SJA, Baas P. Optimal Therapy of Advanced Stage Mesothelioma. *Curr Treat Options Oncol*. 2017 Aug;18(8):48. doi: 10.1007/s11864-017-0488-7. PMID: 28681207.

Disselhorst MJ, Baas P. Chemotherapy options versus “novel” therapies: how should we treat patients with malignant pleural mesothelioma. *Transl Lung Cancer Res*. 2020 Feb;9(Suppl 1):S77-S85. doi: 10.21037/tlcr.2020.01.16. PMID: 32206573; PMCID: PMC7082258.

Baas P, **Disselhorst MJ**. ESMO Handbook Immuno-Oncology; Chapter 2.3.3 Mesothelioma. 2018. ISBN: 978-88-941795-7-6

Disselhorst MJ, Quispel-Janssen J, Lalezari F, Monkhurst K, de Vries JF, van der Noort V, Harms E, Burgers S, Baas P. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. *Lancet Respir Med*. 2019 Mar;7(3):260-270. doi: 10.1016/S2213-2600(18)30420-X. Epub 2019 Jan 16. PMID: 30660511.

Mankor JM*, **Disselhorst MJ***, Poncin M, Baas P, Aerts JGJV, Vroman H. Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials. *EBioMedicine*. 2020 Dec;62:103040. doi: 10.1016/j.ebiom.2020.103040. Epub 2020 Nov 7. PMID: 33166791; PMCID: PMC7658658.
*equal contribution

Disselhorst MJ, de Vries R, Quispel-Janssen J, Wolf-Lansdorf M, Sterk PJ, Baas P. Nose in malignant mesothelioma-Prediction of response to immune checkpoint inhibitor treatment. *Eur J Cancer*. 2021 Jul;152:60-67. doi: 10.1016/j.ejca.2021.04.024. Epub 2021 Jun 1. PMID: 34087572.

Disselhorst MJ, Lubeck Y, van der Noort V, Quispel-Janssen J, Seignette IM, Sanders J, Peters D, Hooijberg E, Baas P. Immune cells in mesothelioma microenvironment: simpliscit marker of response to nivolumab plus ipilimumab? - short communication. Accepted for publication in Lung Cancer

Kosari F, **Disselhorst M**, Yin J, Peikert T, Udell J, Johnson S, Smadbeck J, Murphy S, McCune A, Karagouga G, Desai A, Schaefer-Klein J, Borad MJ, Cheville J, Vasmatazis G, Baas P, Mansfield AS. Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors. *J Thorac Oncol*. 2021 Nov 17:S1556-0864(21)03319-0. doi: 10.1016/j.jtho.2021.10.022. Epub ahead of print. PMID: 34800701.

Other publications

Quispel-Janssen J, van der Noort V, de Vries JF, Zimmerman M, Lalezari F, Thunnissen E, Monkhorst K, Schouten R, Schunselaar L, **Disselhorst M**, Klomp H, Hartemink K, Burgers S, Buikhuisen W, Baas P. Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. *J Thorac Oncol*. 2018 Oct;13(10):1569-1576. doi: 10.1016/j.jtho.2018.05.038. Epub 2018 Jun 14. PMID: 29908324.

Baas P, **Disselhorst M**. Immuno-oncology in malignant pleural mesothelioma. *Lancet Respir Med*. 2018 Jun;6(6):408-410. doi: 10.1016/S2213-2600(18)30176-0. Epub 2018 May 15. PMID: 29773327.

Curriculum vitae

Maria Johanna Disselhorst was born on June 27th 1981 in Castricum, The Netherlands. She graduated from the gymnasium in Castricum in 1999. After one year of health sciences in Maastricht she started medical school at the VU medical center in Amsterdam in 2000. In 2007 she graduated as a medical doctor.

After a few years working as a resident in internal medicine, cardiology, pulmonary medicine, emergency room and intensive care unit, she started her training as a chest physician at the VU medical center. After finishing this in 2017 she started working as a fellow thoracic oncology at the Antoni van Leeuwenhoek – Nederlands Kanker Instituut, combining clinical work with a PhD trajectory.

In 2020 she started as a chest physician in NoordWest Ziekenhuis groep in Alkmaar, with a focus on thoracic oncology.

